Standard BioTools Inc.
LAB
$0.67
$0.023.51%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 170.46% | 189.85% | 19.61% | -62.61% | -65.23% |
| Total Depreciation and Amortization | -40.74% | -27.15% | -36.32% | 110.17% | -13.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -573.14% | -802.20% | 1,145.82% | 1,744.70% | 861.47% |
| Change in Net Operating Assets | -127.34% | -151.63% | -78.68% | 83.13% | 29.36% |
| Cash from Operations | 13.54% | 18.52% | 48.18% | 39.21% | 26.87% |
| Capital Expenditure | 81.90% | 64.28% | -29.37% | -259.96% | -613.04% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -100.49% | -100.49% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -483.15% | -821.91% | -12.23% | 2,693.85% | 319.20% |
| Cash from Investing | 415.99% | 241.36% | -92.45% | -81.14% | -87.89% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -482.50% | -435.28% |
| Issuance of Common Stock | 4.77% | 90.89% | 58.50% | 48.48% | 57.24% |
| Repurchase of Common Stock | -70.08% | -245.34% | 95.67% | 96.44% | 96.90% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | 100.00% |
| Cash from Financing | 100.61% | 100.69% | 100.56% | -11.14% | -8.35% |
| Foreign Exchange rate Adjustments | -77.45% | 288.68% | 220.98% | 439.20% | 658.06% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 200.93% | 184.82% | -139.14% | -160.79% | -185.86% |